GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » Capex-to-Revenue

Eargo (EAR) Capex-to-Revenue : 0.00 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Eargo Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Eargo's Capital Expenditure for the three months ended in Sep. 2023 was $-0.02 Mil. Its Revenue for the three months ended in Sep. 2023 was $8.27 Mil.

Hence, Eargo's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.00.


Eargo Capex-to-Revenue Historical Data

The historical data trend for Eargo's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eargo Capex-to-Revenue Chart

Eargo Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial 0.11 0.12 0.07 0.15 0.08

Eargo Quarterly Data
Dec17 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.02 0.01 0.02 -

Competitive Comparison of Eargo's Capex-to-Revenue

For the Medical Devices subindustry, Eargo's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eargo's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Eargo's Capex-to-Revenue falls into.



Eargo Capex-to-Revenue Calculation

Eargo's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3.087) / 37.248
=0.08

Eargo's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.019) / 8.27
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eargo  (NAS:EAR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Eargo Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Eargo's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Eargo (EAR) Business Description

Traded in Other Exchanges
N/A
Address
2665 North First Street, Suite 300, San Jose, CA, USA, 95134
Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.
Executives
Mark Thorpe officer: Chief Accounting Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie officer: Chief Operating Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis officer: Chief Financial Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen director, officer: President and CEO C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence director C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu director 411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson director C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo director 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB